NHRC Directs Centre, ICMR To File Report on Improper Drug Trials in Hyderabad

Hyderabad: The National Human Rights Commission (NHRC) has directed the Union health ministry, and the Indian Council for Medical Research (ICMR) to investigate the case involving a drug trial in Hyderabad last year which resulted in one of the trial participants suffering a heart attack.

The NHRC, in its directions issued on Wednesday, said allegations in a complaint it received over the issues faced by the participant, “prima facie seem to be violations of the human rights of the victim.” In the directions, the NHRC made it clear that the complaint must be investigated and an action taken report submitted to it in four weeks.

The complaint with NHRC was filed by human rights lawyer Rama Rao Immaneni following reports in Deccan Chronicle on the trials and tribulations of Dipanker Dey, a migrant worker who signed up for the trial that was being conducted by a city-based clinical research organisation (CRO) for a breast cancer drug. During the course of the trial, Dey, reportedly suffered a cardiac arrest but was not attended to by the CRO which sent him off to Gandhi Hospital to get treatment.

Dey had also complained then when he was fighting with the CRO that he was under intense pressure from the CRO to delete his posts on social media platforms about the problems he was facing both health and financial wise, finally had said he was willing to take any compensation he can get and give a letter to the CRO giving it a clean chit, and after a nearly two month struggle, returned to his hometown Kolkata.

“He was under severe duress and with no one helping him and the CRO pressuring him for any compensation, he was likely tricked by agents to take whatever money the company gave him in return for his silence. Now that the NHRC has initiated action, he will hopefully receive justice finally,” Rama Rao Immaneni said.

In its notice to the Union health ministry, the NHRC said “the complainant alleged that a poor and illiterate labourer was made to participate in a clinical trial for a breast cancer drug by an agent who made false promises. During the trial, the victim suffered a heart attack but did not receive proper medical care until the police intervened.”

The NHRC continued, “Afterwards, the clinical research organisation and the sponsoring pharmaceutical company pressured the victim to sign a false declaration claiming he was cured. When he refused, the ethics committee and others involved failed to report the adverse event to the drug authorities. As a result, the victim suffered a second heart stroke, leading to permanent disability and loss of livelihood.”

“The complainant has requested that the licenses of the companies involved be cancelled and that they be ordered to pay compensation of Rs.1 crore to the victim. They also requested legal action against those responsible for exploiting poor and uneducated individuals in clinical trials,” the NHRC said.

Related Posts

PGIMS recalls drug amid probe into deaths

The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

NPPA list brings little relief: No price cut for 25% cancer drugs

Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Medicines that cure Us are making Our Environment Sick

Medicines that cure Us are making Our Environment Sick

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

PGIMS recalls drug amid probe into deaths

PGIMS recalls drug amid probe into deaths

NPPA list brings little relief: No price cut for 25% cancer drugs

NPPA list brings little relief: No price cut for 25% cancer drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

For Aakash Healthcare, Community People are Apples of its Eyes

For Aakash Healthcare, Community People are Apples of its Eyes